|
RU2014138474A
(ru)
|
2012-02-24 |
2016-04-10 |
СтемСентРкс, Инк. |
Новые модуляторы и способы применения
|
|
CA2881966C
(en)
|
2012-08-24 |
2020-10-06 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
|
MX2015010682A
(es)
|
2013-02-22 |
2016-05-31 |
Stemcentrx Inc |
Nuevos conjugados de anticuerpos y usos de los mismos.
|
|
PE20160674A1
(es)
*
|
2013-08-28 |
2016-07-21 |
Stemcentrx Inc |
Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
|
|
CA2922529A1
(en)
|
2013-08-28 |
2015-03-05 |
Stemcentrx, Inc. |
Novel sez6 modulators and methods of use
|
|
WO2015127407A1
(en)
|
2014-02-21 |
2015-08-27 |
Stemcentrx, Inc. |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
MA41645A
(fr)
*
|
2015-03-04 |
2018-01-09 |
Abbvie Stemcentrx Llc |
Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
|
|
GB201506407D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506399D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506405D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506388D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506393D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506394D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506389D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
MX383614B
(es)
|
2015-05-21 |
2025-03-14 |
Harpoon Therapeutics Inc |
Proteinas de union triespecificas y metodos de uso.
|
|
CN108025085A
(zh)
*
|
2015-06-23 |
2018-05-11 |
拜耳制药股份公司 |
Ksp抑制剂与抗b7h3抗体的抗体药物缀合物(adc)
|
|
MX2018002166A
(es)
*
|
2015-08-20 |
2018-09-12 |
Abbvie Stemcentrx Llc |
Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
|
|
GB201602363D0
(en)
*
|
2016-02-10 |
2016-03-23 |
Adc Therapeutics Sa And Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
KR20250065434A
(ko)
|
2016-03-01 |
2025-05-12 |
이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
|
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
EP3474854A4
(en)
|
2016-06-27 |
2020-02-19 |
The Regents of The University of California |
CANCER TREATMENT COMBINATIONS
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US11160872B2
(en)
|
2017-02-08 |
2021-11-02 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3612537B1
(en)
|
2017-04-18 |
2022-07-13 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
CN110536703B
(zh)
|
2017-04-20 |
2024-07-12 |
Adc治疗有限公司 |
使用抗axl抗体-药物缀合物的组合疗法
|
|
UA127900C2
(uk)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Схема дозування для введення adc до cd19
|
|
CN108743968B
(zh)
*
|
2017-06-20 |
2022-04-19 |
成都百利多特生物药业有限责任公司 |
半胱氨酸改造的抗体-毒素偶联物(tdc)定点偶联位点筛选
|
|
RS62928B1
(sr)
|
2017-08-18 |
2022-03-31 |
Medimmune Ltd |
Konjugati pirolobenzodiazepina
|
|
SG11202001430SA
(en)
|
2017-09-29 |
2020-04-29 |
Daiichi Sankyo Co Ltd |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
SI3694529T1
(sl)
|
2017-10-13 |
2024-10-30 |
Harpoon Therapeutics, Inc. |
Trispecifične beljakovine in načini uporabe
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
US20200345863A1
(en)
*
|
2017-10-23 |
2020-11-05 |
Mablink Bioscience |
Ligand-drug-conjugate comprising a single molecular weight polysarcosine
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2019217145A1
(en)
*
|
2018-05-08 |
2019-11-14 |
Phanes Therapeutics, Inc. |
Anti-dll3 antibodies and uses thereof
|
|
BR112020023330A2
(pt)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
porção de ligação para ativação condicional de moléculas de imunoglobulina
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
JP7611825B2
(ja)
|
2018-08-02 |
2025-01-10 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
|
|
US20220193250A1
(en)
|
2018-08-02 |
2022-06-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
US20210330802A1
(en)
*
|
2018-10-10 |
2021-10-28 |
Takeda Pharmaceutical Company Limited |
Method for producing antibody-drug conjugate
|
|
US20220016257A1
(en)
|
2018-11-14 |
2022-01-20 |
Daiichi Sankyo Company, Limited |
Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
|
|
ES2967878T3
(es)
|
2019-03-15 |
2024-05-06 |
Medimmune Ltd |
Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
|
|
TWI856078B
(zh)
|
2019-03-25 |
2024-09-21 |
日商第一三共股份有限公司 |
抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
|
|
WO2020196475A1
(ja)
|
2019-03-25 |
2020-10-01 |
第一三共株式会社 |
抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
|
|
BR112021017350A2
(pt)
|
2019-03-27 |
2021-11-16 |
Daiichi Sankyo Co Ltd |
Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
|
|
KR20220008866A
(ko)
|
2019-05-14 |
2022-01-21 |
하푼 테라퓨틱스, 인크. |
EpCAM 결합 단백질 및 사용 방법
|
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
|
EP4041392A1
(en)
|
2019-10-08 |
2022-08-17 |
Nectin Therapeutics Ltd. |
Antibodies against the poliovirus receptor (pvr) and uses thereof
|
|
WO2021154476A1
(en)
*
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
US12624120B2
(en)
|
2020-01-31 |
2026-05-12 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (TfR) antibody and uses thereof
|
|
KR20230061360A
(ko)
|
2020-09-02 |
2023-05-08 |
다이이찌 산쿄 가부시키가이샤 |
신규 엔도-β-N-아세틸글루코사미니다아제
|
|
WO2022153194A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
CN117980006A
(zh)
|
2021-07-09 |
2024-05-03 |
达因疗法公司 |
用于治疗肌养蛋白病的肌肉靶向复合物和制剂
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
EP4378955A4
(en)
*
|
2021-07-30 |
2025-10-22 |
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co Ltd |
ANTI-DLL3 ANTIBODY AND PREPARATION METHOD THEREOF, DRUG CONJUGATE AND APPLICATION THEREOF
|
|
CR20240135A
(es)
*
|
2021-09-17 |
2024-05-17 |
Wuxi Biologics Ireland Ltd |
Moléculas de unión a d3 y usos de estas
|
|
KR20240113514A
(ko)
|
2021-11-30 |
2024-07-22 |
다이이찌 산쿄 가부시키가이샤 |
프로테아제 분해성 마스크 항체
|
|
EP4454662A4
(en)
*
|
2021-12-23 |
2025-04-23 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
ANTI-DLL3 ANTIBODY AND PHARMACEUTICAL USE THEREOF, AND ANTIBODY-DRUG CONJUGATE CONTAINING AN ANTI-DLL3 ANTIBODY
|
|
KR20240141757A
(ko)
|
2022-02-09 |
2024-09-27 |
다이이찌 산쿄 가부시키가이샤 |
환경 응답성 마스킹 항체 및 그 이용
|
|
TW202346322A
(zh)
|
2022-03-02 |
2023-12-01 |
日商第一三共股份有限公司 |
含Ｆｃ分子之製造方法
|
|
KR20250004770A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
|
|
EP4534101A1
(en)
|
2023-10-02 |
2025-04-09 |
Eli Lilly and Company |
Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
|
|
WO2025190281A1
(en)
*
|
2024-03-11 |
2025-09-18 |
Lepu Biopharma Co., Ltd. |
Anti-dll3 antibodies and uses thereof
|
|
CN119119255B
(zh)
*
|
2024-09-20 |
2026-03-03 |
广东省生物技术研究院(广东省实验动物监测中心) |
一种猪急性腹泻综合征冠状病毒的刺突蛋白抗原表位肽及其单克隆抗体与应用
|